Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.69 |
| ▸ | AHCY | P23526 | 6/20 | 0.68 |
| ▸ | NADK | O95544 | 1/20 | 0.68 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.68 |
| ▸ | PNMT | P11086 | 1/20 | 0.68 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.68 |
| ▸ | GNMT | Q14749 | 3/20 | 0.68 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17551942 | 0.85 | GNMT (0.80) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL6901855 | 0.85 | GNMT (0.80) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL19434095 | 0.85 | GNMT (0.80) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL9550942 | 0.85 | GNMT (0.80) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL21311164 | 0.83 | ADORA3 (0.70) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL3299462 | 0.83 | ADORA1 (0.61) | DOT1LAHCYNADKDPP4 | |
| SCHEMBL6904454 | 0.83 | AHCY (0.68) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL21243035 | 0.83 | DOT1L (0.84) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL6900787 | 0.82 | GNMT (0.69) | DOT1LAHCYNADKDNMT3BPNMT | |
| SCHEMBL6902821 | 0.82 | GNMT (0.74) | DOT1LAHCYNADKDNMT3BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | AGOURON PHARMACEUTICALS INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043959-A1 | Combination therapies for treating methylthioadenosine phosphorylase deficient cells | APRT, MTAP, TYMP | DOT1L 1250/4885AHCY 62/4885NADK 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.